Kovalishyn Vasyl, Brovarets Volodymyr, Blagodatnyi Volodymyr, Kopernyk Iryna, Hodyna Diana, Chumachenko Svitlana, Shablykin Oleg, Kozachenko Oleksandr, Vovk Myhailo, Barus Marianna, Bratenko Myhailo, Metelytsia Larysa
Institute of Bioorganic Chemistry & Petrochemistry, National Academy of Science of Ukraine, 1 Murmanska Street, 02660, Kyiv, Ukraine.
Curr Drug Discov Technol. 2017;14(1):25-38. doi: 10.2174/1570163813666161108125227.
The increasing rate of appearance of multidrug-resistant strains of Mycobacterium tuberculosis (MDR-TB) is a serious problem at the present time. MDR-TB forms do not respond to the standard treatment with the commonly used drugs and can take some years or more to treat with drugs that are less potent, more toxic and much more expensive.
The goal of this work is to identify the novel effective drug candidates active against MDR-TB strains through the use of methods of cheminformatics and computeraided drug design.
This paper describes Quantitative Structure-Activity Relationships (QSAR) studies using Artificial Neural Networks, synthesis and in vitro antitubercular activity of several potent compounds against H37Rv and resistant Mycobacterium tuberculosis (Mtb) strains.
Eight QSAR models were built using various types of descriptors with four publicly available structurally diverse datasets, including recent data from PubChem and ChEMBL. The predictive power of the obtained QSAR models was evaluated with a cross-validation procedure, giving a q2=0.74-0.78 for regression models and overall accuracy 78.9-94.4% for classification models. The external test sets were predicted with accuracies in the range of 84.1-95.0% (for the active/inactive classifications) and q2=0.80- 0.83 for regressions. The 15 synthesized compounds showed inhibitory activity against H37Rv strain whereas the compounds 1-7 were also active against resistant Mtb strain (resistant to isoniazid and rifampicin).
The results indicated that compounds 1-7 could serve as promising leads for further optimization as novel antibacterial inhibitors, in particular, for the treatment of drug resistance of Mtb forms.
目前,结核分枝杆菌多重耐药菌株(MDR-TB)的出现率不断上升,这是一个严重的问题。MDR-TB菌株对常用药物的标准治疗无反应,使用效力较低、毒性更大且价格昂贵得多的药物进行治疗可能需要数年或更长时间。
本研究的目标是通过化学信息学和计算机辅助药物设计方法,确定对MDR-TB菌株具有活性的新型有效候选药物。
本文描述了使用人工神经网络的定量构效关系(QSAR)研究、几种强效化合物对H37Rv和耐药结核分枝杆菌(Mtb)菌株的合成及体外抗结核活性。
使用各种类型的描述符,利用四个公开可用的结构多样的数据集构建了八个QSAR模型,包括来自PubChem和ChEMBL的最新数据。通过交叉验证程序评估所得QSAR模型的预测能力,回归模型的q2=0.74-0.78,分类模型的总体准确率为78.9-94.4%。外部测试集的预测准确率在84.1-95.0%(活性/非活性分类)范围内,回归的q2=0.80-0.83。15种合成化合物对H37Rv菌株显示出抑制活性,而化合物1-7对耐药Mtb菌株(对异烟肼和利福平耐药)也有活性。
结果表明,化合物1-7有望作为新型抗菌抑制剂进一步优化的先导化合物,特别是用于治疗Mtb菌株的耐药性。